Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size

Wenzel M. Hackeng, Lodewijk A.A. Brosens, Joo Young Kim, Roderick O'Sullivan, You Na Sung, Ta Chiang Liu, Dengfeng Cao, Michelle Heayn, Jacqueline Brosnan-Cashman, Soyeon An, Folkert H.M. Morsink, Charlotte M. Heidsma, Gerlof D. Valk, Menno R. Vriens, Els Nieveen Van Dijkum, G. Johan A. Offerhaus, Koen M.A. Dreijerink, Herbert Zeh, Amer H. Zureikat, Melissa HoggKenneth Lee, David Geller, J. Wallis Marsh, Alessandro Paniccia, Melanie Ongchin, James F. Pingpank, Nathan Bahary, Muaz Aijazi, Randall Brand, Jennifer Chennat, Rohit Das, Kenneth E. Fasanella, Asif Khalid, Kevin McGrath, Savreet Sarkaria, Harkirat Singh, Adam Slivka, Michael Nalesnik, Xiaoli Han, Marina N. Nikiforova, Rita Teresa Lawlor, Andrea Mafficini, Boris Rusev, Vincenzo Corbo, Claudio Luchini, Samantha Bersani, Antonio Pea, Sara Cingarlini, Luca Landoni, Roberto Salvia, Massimo Milione, Michele Milella, Aldo Scarpa, Seung Mo Hong, Christopher M. Heaphy, Aatur D. Singhi

Research output: Contribution to journal › Article › peer-review

57 Scopus citations

Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size

Fingerprint

Medicine & Life Sciences